Navigation Links
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Date:11/4/2008

n of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obl
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... JOLLA, Calif. , Nov. 26, 2014   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and CEO of Regulus, ... Annual Piper Jaffray Healthcare Conference at the New ... 2:00 p.m. EST.  The presentation will be webcast at ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
(Date:11/26/2014)... 26, 2014 The medical magnetic resonance ... of 4%, with world market revenues for 2013 ... and other types of medical imaging have led ... numerous medical conditions in children and adults, each ... report, Medical Imaging Markets , analyzes the ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... ... of Body Mass Index -, PHILADELPHIA, Oct. 16 ... been,established, but healthcare professionals have had little guidance as to,whether ... with GERD. Two studies about obesity and its,relationship to GERD ...
... to File Supplemental New Drug Application with FDA in First ... ... FRANCISCO, Calif., Oct. 16 Anesiva,Inc. (Nasdaq: ANSV ) today ... randomized, double-blind study,with 699 adult patients met its primary endpoint, demonstrating ...
Cached Medicine Technology:Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 2Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 3Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 4Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 5Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 2Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 3Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 4Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 5
(Date:11/27/2014)... In order to enable people to adapt to ... easy way to avoid touching a toilet seat and/or lid ... prototype of the patent-pending Toilet Tamer, a device that enables ... lid in a more sanitary manner. It avoids direct contact ... it promotes good hygiene and peace of mind. The portable ...
(Date:11/27/2014)... Now that Thanksgiving is finally here ... Emassagechair.com has announced its eagerly awaited, once ... , Negotiating on behalf of their customers, and drawing ... Emassagechair.com has generated significant buzz in the industry with ... yet. , Shoppers are excited for significant savings available ...
(Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
(Date:11/27/2014)... 27, 2014 Developers and plugin specialist of ... entitled ProPip, taking FCPX to the next level. , “ProPip ... a few clicks of a mouse,” said Christina Austin, CEO ... our users will appreciate.” , With ProPip users can show ... possibilities truly endless. ProPip is great for commentaries, news casting, ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... Millions of postmenopausal women suffer from sexual dysfunctions- ... physiological and psychological problems. ,However if the ... these problems can be treated properly. Almost all ... develop changes in genital organs-particularly a condition known ...
... breast lumps are too small to be picked up by ... a potential candidate for breast cancer. But to offset this ... Baltimore headed by Dr. Saraswathi Sukumar, have devised a new ... a new method called ductal lavage. Ductal lavage, involves "washing" ...
... with diabetes, the most painful and bothering one is the ... part according to many diabetics is the finger stick. There ... times a day for more than ten to twenty years ... pain and discomfort associated with them. But researchers and manufacturers ...
... of Anti-dumping and Allied Duties, under the ministry ... duties on paracetamol from China and Taiwan. This ... used drug on basis of a petition filed ... and Sri Krishna Pharmaceuticals; Solapur based Vamsi Labs, ...
... therapy, complimentary and alternative medicine seem to be more ... new study. Among 191 HIV-positive outpatients surveyed about their ... had used alternative therapies at some point to control ... findings appear in the current issue of The journal ...
... wound healing in depressed people is four times slower than ... place in the latest issue of the journal, “Psychosomatic Medicine”. ... the rate of wound healing, according to the researchers. Depression ... immune system, which may keep a wound from healing on ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: